Loading... Please wait...Applications
New Products
Our Newsletter
- Home
- Invasive Electrodes
- AgilePulse In Vivo System
- Home
- In Vivo Transfection
- AgilePulse In Vivo System
AgilePulse In Vivo System
APPLICATIONS
- Vaccine Development
- Intra-dermal Gene Delivery
- Intra-muscular Gene Delivery
- Intra-tumor Gene Delivery
MAXIMUM EFFICIENCY DNA VACCINATION DELIVERY
Effectively introduced DNA vaccines represent a powerful and safe means for stimulating an immune response that recognizes and eliminates target molecules in the body. However, traditional DNA vaccine delivery systems, such as gene gun delivery, suffer from poor efficiency. The BTX AgilePulse™ In Vivo System used for vaccine development and gene therapy provides an intra-dermal/muscular electroporation solution to produce maximum transfection efficiency. The AgilePulse In Vivo System can be purchased with software supporting intra-dermal (ID) or intra-muscular (IM) applications.
For vaccine applications, DNA vaccination through the dermal layer is preferred since it is an easily accessible site that is immunologically active. After direct injection of plasmid DNA in the dermal layer, a programmed sequence of electric pulses is applied through a miniature parallel needle electrode array to promote cellular uptake and transfection. Cells in the surrounding tissue are transfected, including dendritic antigen-presenting cells and mesenchymal origin cells. Gene expression simulates the immune system to respond to the secreted antigen. Gene expression in skin is 100-fold higher when delivery is enhanced by electroporation compared to simply injecting plasmid DNA (Roos, et. al. 2009).
Use of the AgilePulse HT system (formerly Cyto LVT-P) is subject to an annual license agreement between Cellectis bioresearch and the purchaser. Please contact Cellectis bioresearch cytopulse@cellectis.com for further details.
Use of the Hybrimune® device is subject to an annual license agreement between Cellectis bioresearch and the purchaser. Please contact Cellectis bioresearch cytopulse@cellectis.com for further details.
Use of the Agile Pulse In Vivo system (formerly the DermaVax device) is not authorized for any veterinary and human therapeutic uses. Contact Cellectis therapeutics contact@cellectis-therapeutics.com for such uses.
For Research Purposes only.
| User Interface | Touch Screen Display, Footswitch |
| Voltage Range | 50 to 1000 volts |
| Pulse Width Range | 0.050 to 10 ms |
| Pulse Interval | 0.200 to 1000 ms (5 kHz to 1 Hz) |
| Data Export | USB Flash Key |
| Dimensions | 32 cm w x 20 cm h x 40 cm |
| (with handle) | (12.6 in w x 7.9 in h x 15.7 in) |
| Weight | 25 pounds, 11.3 kg |
| Operating Temperature | 10 to 40 oC |
| Mains Voltage | 100 to 250 VAC |
| Fuse | 5 Amp Slo-Blo®, 5 mm x 20 mm |
| Item # | Description |
|
47-0400N 47-0500N |
Agile Pulse In Vivo ID system Agile Pulse In Vivo IM system
|
BTX Monthly Tech Trends Articles
For further references regarding specific applications and optimization, please contact BTX Technical Support:
BTX-Division of Harvard Apparatus
84 October Hill Road
Holliston, MA 01746
Phone: 1-508-893-8999
Toll Free: 1-800-272-2775
Fax: 1-508-429-5732
Email: techsupport.btx@harvardapparatus.com
If outside the United States or Canada: call 508-893-8999 or
contact your nearest BTX Distributor
Lundberg K, Roos A-K, Pavlenko M, Wehrum D, Pisa P. Peptide specificity of HLA-A2-restricted CD8+ T cell responses induced with DNA vaccines coding for human and rhesus PSA. Vaccine. 2009 Mar 4; 27(10):1557-65.
Bråve A, Hallengärd D, Gudmundsdotter L, Stout R, Walters R, Wahren B, Hallermalm K. Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen. Vaccine. 2009 Jun 8; 27(28):3692-6.
Roos, A-K, Eriksson, F, Walters, D, Pisa, P, King, A. Optimization of skin electroporation in mice to increase tolerability of DNA vaccine delivery to patients. Molecular Therapy, 2009 Sep; 17(9):1637-42.
Lladser A, Ljungberg K, Tufvesson H, Tazzari M, Roos A, Quest FG, Kiessling R. Intradermal electroporation with a survivin DNA vaccine induces CTLs against a self-epitope, suppresses angiogenesis and confers long-term protection against mouse melanoma. Cancer Immunol Immunother. 2010 Jan; 59(1): 81-92.
